UroGen Pharma (URGN) Amortization of Deferred Charges (2019 - 2021)

UroGen Pharma (URGN) has 7 years of Amortization of Deferred Charges data on file, last reported at $577000.0 in Q1 2026.

• Quarterly Amortization of Deferred Charges rose 35.76% year-over-year to $577000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 114.04% YoY) and the FY2025 annual result came in at $2.1 million, up 145.51% from the prior year.
• Amortization of Deferred Charges retreated to $577000.0 in Q1 2026, from $604000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $604000.0 in Q4 2025 to a low of $193000.0 in Q2 2024.
• A 5-year average of $313764.7 and a median of $234000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges dropped 16.6% — and 2025, when it soared 182.32%.
• Tracing URGN's Amortization of Deferred Charges over 5 years: stood at $214000.0 in 2022, then gained by 9.35% to $234000.0 in 2023, then increased by 1.71% to $238000.0 in 2024, then soared by 153.78% to $604000.0 in 2025, then declined by 4.47% to $577000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $577000.0 (Q1 2026), $604000.0 (Q4 2025), and $559000.0 (Q3 2025), per Business Quant data.